VisionGate, a developer of non-invasive test for the early detection of lung cancer and related applications, has declared the automation of its Cell-CT system. This system is the company’s imaging platform that creates 3D biosignatures of high-resolution from intact cells.
The BRDG-SPAN program (Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies) of the National Institutes of Health (NIH) awarded the company with $2.6 M grant for its automated system. VisionGate also declared about its representation at the OneMedForum 2012 Finance Conference on Tuesday, January 10, 2012 at San Francisco.
LuCED test, a non-invasive test for lung cancer screening, is the first diagnostic application for the Cell-CT system. This test is available with x-ray computed tomography (CT) scans to detect lung cancer at early stages.
At the 14th World Conference on Lung Cancer, the detection of cancer cells in sputum samples by the Cell-CT and LuCED platform was demonstrated by VisionGate.
LuCED and the Cell-CT platform create clear 3D images of cells in sputum that is examined by the system to identify biosignatures, or other characteristic features related to potential malignancy.
LuCED, used along with x-ray CT screening, is effective in reducing the high-risk of lung cancer deaths, minimizing the occurrences of false positives, thereby ensuring the effective utilization of this approach towards cost-effective lung cancer screening on a collective scale.
The Cell-CT automated system optimizes the advanced optics mechanism and computational technology that are able to capture images very rapidly, representing scanned objects into 3D digital images. The complete Cell-CT system has been custom designed by engineers and scientists at VisionGate.